UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments

Current atherosclerosis reports, 2024-02, Vol.26 (2), p.35-44

2024

Volltextzugriff (PDF)

Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels

International journal of molecular sciences, 2022-08, Vol.23 (16), p.9417

2022

Volltextzugriff (PDF)

The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease

Pharmacological research, 2023-11, Vol.197, p.106972-106972, Article 106972

2023

Volltextzugriff (PDF)

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial

Journal of clinical lipidology, 2023-07, Vol.17 (4), p.491-503

2023

Volltextzugriff (PDF)

Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial

Journal of Atherosclerosis and Thrombosis, 2024, pp.64828

2024

Volltextzugriff (PDF)

CETP and SGLT2 inhibitor combination therapy increases glycemic control: a 2x2 factorial Mendelian randomization analysis

Frontiers in endocrinology (Lausanne), 2024-06, Vol.15, p.1359780

2024

Volltextzugriff (PDF)

Effects of the dual peroxisome proliferator–activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes

The American heart journal, 2015-07, Vol.170 (1), p.117-122

2015

Volltextzugriff (PDF)

Effect of Short-Term Rosuvastatin Treatment on Estimated Glomerular Filtration Rate

The American journal of cardiology, 2006-06, Vol.97 (11), p.1602-1606

2006

Volltextzugriff (PDF)

Obicetrapib does not accumulate in adipose tissue: Results from studies in man and non-human primates

Atherosclerosis, 2024-08, Vol.395

2024

Volltextzugriff (PDF)

Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?

Cardiovascular research, 2022-11, Vol.118 (14), p.2919-2931

2022

Volltextzugriff (PDF)

Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial

Nature medicine, 2022-08, Vol.28 (8), p.1672-1678

2022

Volltextzugriff (PDF)

Obicetrapib treatment increases pre-beta1 HDL and lipophilic antioxidants in the ocean and ROSE2 studies

Atherosclerosis, 2024-08, Vol.395

2024

Volltextzugriff (PDF)

Obicetrapib demonstrates significant reductions of Lp(a) on top of high-intensity statins

Atherosclerosis, 2024-08, Vol.395

2024

Volltextzugriff (PDF)

Obicetrapib Does Not Accumulate in Adipose Tissue: Results from Studies in Man and Non-human Primates

Journal of clinical lipidology, 2024-07, Vol.18 (4), p.e563-e563

2024

Volltextzugriff (PDF)

Obicetrapib alone and in combination with ezetimibe reduces non-HDL-cholesterol by enhanced LDL-receptor-mediated VLDL clearance and increased net fecal sterol excretion in apoe3-leiden.cetp mice

Atherosclerosis, 2024-08, Vol.395

2024

Volltextzugriff (PDF)

Obicetrapib alone and in combination with ezetimibe reduces atherosclerotic lesion size and severity in ApoE3-Leiden.CETP mice

Atherosclerosis, 2024-08, Vol.395

2024

Volltextzugriff (PDF)

Obicetrapib Treatment Increases Pre-Beta1 HDL and Lipophilic Antioxidants in the Ocean and Rose2 Studies

Journal of clinical lipidology, 2024-07, Vol.18 (4), p.e566-e567

2024

Volltextzugriff (PDF)

Obicetrapib Demonstrates Significant Reductions Of Lp(a) On Top Of High-intensity Statins

Journal of clinical lipidology, 2024-07, Vol.18 (4), p.e563-e564

2024

Volltextzugriff (PDF)

Synergistic Effect of Obicetrapib and Ezetimibe on Circulating LDL Particles

Journal of clinical lipidology, 2024-07, Vol.18 (4), p.e566-e566

2024

Volltextzugriff (PDF)

Guiding Dyslipidemia Treatment: A Population Pharmacokinetic–Pharmacodynamic Framework for Obicetrapib

Journal of clinical pharmacology, 2024-09, Vol.64 (9), p.1150-1164

2024

Volltextzugriff (PDF)

A Randomized, Parallel, Open-Label, Single-Dose and Multiple-Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in China

Journal of clinical pharmacology, 2024-08

2024

Volltextzugriff (PDF)

Obicetrapib Lowers LDL-C in Patients Taking High Intensity Statins - Results from the ROSE Clinical Trial

Journal of clinical lipidology, 2022-07, Vol.16 (3), p.e67-e68

2022

Volltextzugriff (PDF)

Obicetrapib Alone and with Ezetimibe Reduces Non-HDL-C by Enhanced LDL-Receptor-Mediated VLDL Clearance and Increased Net Fecal Sterol Excretion

Journal of clinical lipidology, 2024-07, Vol.18 (4), p.e552-e552

2024

Volltextzugriff (PDF)

Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program

Future cardiology, 2016-07, Vol.12 (4), p.405-418

2016

Volltextzugriff (PDF)

The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial

European heart journal, 2014-07, Vol.35 (27), p.1792-1800

2014

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(6)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments

Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels

The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial

Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial

CETP and SGLT2 inhibitor combination therapy increases glycemic control: a 2x2 factorial Mendelian randomization analysis

Effects of the dual peroxisome proliferator–activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes

Effect of Short-Term Rosuvastatin Treatment on Estimated Glomerular Filtration Rate

Obicetrapib does not accumulate in adipose tissue: Results from studies in man and non-human primates

Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?

Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial

Obicetrapib treatment increases pre-beta1 HDL and lipophilic antioxidants in the ocean and ROSE2 studies

Obicetrapib demonstrates significant reductions of Lp(a) on top of high-intensity statins

Obicetrapib Does Not Accumulate in Adipose Tissue: Results from Studies in Man and Non-human Primates

Obicetrapib alone and in combination with ezetimibe reduces non-HDL-cholesterol by enhanced LDL-receptor-mediated VLDL clearance and increased net fecal sterol excretion in apoe3-leiden.cetp mice

Obicetrapib alone and in combination with ezetimibe reduces atherosclerotic lesion size and severity in ApoE3-Leiden.CETP mice

Obicetrapib Treatment Increases Pre-Beta1 HDL and Lipophilic Antioxidants in the Ocean and Rose2 Studies

Obicetrapib Demonstrates Significant Reductions Of Lp(a) On Top Of High-intensity Statins

Synergistic Effect of Obicetrapib and Ezetimibe on Circulating LDL Particles

Guiding Dyslipidemia Treatment: A Population Pharmacokinetic–Pharmacodynamic Framework for Obicetrapib

A Randomized, Parallel, Open-Label, Single-Dose and Multiple-Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in China

Obicetrapib Lowers LDL-C in Patients Taking High Intensity Statins - Results from the ROSE Clinical Trial

Obicetrapib Alone and with Ezetimibe Reduces Non-HDL-C by Enhanced LDL-Receptor-Mediated VLDL Clearance and Increased Net Fecal Sterol Excretion

Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program

The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial

Suchergebnisse filtern